An update on breast cancer prevention trials
Authors:
- 1 September 2006
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 16 (s2) , 498-501
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialThe Lancet, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Tamoxifen for breast cancer among hysterectomised womenThe Lancet, 2002
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer, 2001
- The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal WomenJAMA, 1999
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998